Madrigal Pharmaceuticals Initiates the MAESTRO-NASH Outcomes Study Evaluating Resmetirom for the Treatment of Patients with Compensated NASH Cirrhosis

Madrigal Pharmaceuticals, Inc. announced initiation of the study of resmetirom, which will noninvasively measure progression to liver decompensation events in approximately 700 patients with compensated NASH cirrhosis.